CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 41 enrolled
Drug / intervention
RAD001drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01830153
NCT01830153Phase 2Completed
CompareCT.gov

A Phase II Multicenter Trial of RAD001 in Patients With Metastatic or Recurrent Sarcomas

Asan Medical Center·interventional·Posted Apr 12, 2013·Updated Apr 12, 2013

In Brief

A Phase 2 clinical trial evaluating RAD001 for Soft Tissue Sarcomas and Bone Sarcomas. Completed, enrolled 41 participants across 8 sites.

Detailed Summary

This trial intends to test the efficacy and safety of RAD001 in patients with advanced sarcoma who failed to conventional chemotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSoft Tissue Sarcomas, Bone Sarcomas
CountriesSouth Korea
CollaboratorsNovartis

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 12, 2013
Enrollment StartApr 1, 2010
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 13.2 years ago

Interventions

RAD001drug